Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Significant Growth in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 27,645 shares, a growth of 172,681.2% from the August 15th total of 16 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 474,592 shares, the days-to-cover ratio is currently 0.1 days.

Oncotelic Therapeutics Trading Down 1.0%

Shares of Oncotelic Therapeutics stock traded down $0.00 during trading hours on Thursday, reaching $0.03. The stock had a trading volume of 268,000 shares, compared to its average volume of 274,358. The firm has a market capitalization of $13.69 million, a price-to-earnings ratio of 0.05 and a beta of -0.24. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01. Oncotelic Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.11. The firm has a 50 day simple moving average of $0.04 and a two-hundred day simple moving average of $0.04.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.